INM

InMed Pharmaceuticals Inc.

Insiders buying nowCIK 1728328

InMed Pharmaceuticals Inc. insider trading

InMed Pharmaceuticals Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.

From SEC filings · last 30 days

Recent INM insider transactions

The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.

SEC Form 4 data, Q3 2024 to Q2 2026

INM insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 3 insiders traded INM on the open market: 21 purchases worth $1.1M and 1 sale worth $43. In the last four quarters alone: 21 purchases ($1.1M) and 0 sales, by 2 insiders.

QuarterBoughtSold
Q2 2026+$1.1M21 buys—
Q1 2026——
Q4 2025——
Q3 2025——
Q2 2025——
Q1 2025——
Q4 2024——
Q3 2024—−$431 sale
Largest purchase
+$312K of INM by Schneeberger Daniel (10% Owner) on May 19, 2026.
Largest sale
−$43 of INM by Mancini Alexandra Diane Janet (Consultant) on Jul 31, 2024.

Open-market transactions through Jun 30, 2026most recent first

  • Vivo Opportunity, LLC

    10% Owner

    +$44.9K

    Jun 08, 2026

    29,518 sh · $1.52

  • Vivo Opportunity, LLC

    10% Owner

    +$4.5K

    Jun 08, 2026

    2,982 sh · $1.52

  • Vivo Opportunity, LLC

    10% Owner

    +$78.4K

    Jun 05, 2026

    49,966 sh · $1.57

  • Vivo Opportunity, LLC

    10% Owner

    +$7.9K

    Jun 05, 2026

    5,045 sh · $1.57

  • Vivo Opportunity, LLC

    10% Owner

    +$9.6K

    Jun 04, 2026

    6,125 sh · $1.57

  • Vivo Opportunity, LLC

    10% Owner

    +$970

    Jun 04, 2026

    618 sh · $1.57

  • Vivo Opportunity, LLC

    10% Owner

    +$11K

    Jun 03, 2026

    7,069 sh · $1.55

  • Vivo Opportunity, LLC

    10% Owner

    +$1.1K

    Jun 03, 2026

    714 sh · $1.55

  • Vivo Opportunity, LLC

    10% Owner

    +$31.5K

    Jun 02, 2026

    20,753 sh · $1.52

  • Vivo Opportunity, LLC

    10% Owner

    +$3.2K

    Jun 02, 2026

    2,095 sh · $1.52

  • Vivo Opportunity, LLC

    10% Owner

    +$23K

    Jun 01, 2026

    14,838 sh · $1.55

  • Vivo Opportunity, LLC

    10% Owner

    +$2.3K

    Jun 01, 2026

    1,498 sh · $1.55

  • Vivo Opportunity, LLC

    10% Owner

    +$25.4K

    May 29, 2026

    16,164 sh · $1.57

  • Vivo Opportunity, LLC

    10% Owner

    +$2.6K

    May 29, 2026

    1,632 sh · $1.57

  • Vivo Opportunity, LLC

    10% Owner

    +$52.2K

    May 21, 2026

    30,882 sh · $1.69

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Don't check INM — let it ping you

Watch every insider filing the minute it clears the SEC

The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.

InMed Pharmaceuticals Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.

Other companies insiders are buying now

Questions

How much INM stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 3 InMed Pharmaceuticals Inc. insiders made 21 open-market purchases worth $1.1M and 1 sale worth $43. In the four quarters to Jun 30, 2026: 21 purchases ($1.1M) and no sales. The largest purchase was Schneeberger Daniel buying $312K on May 19, 2026. The largest sale was Mancini Alexandra Diane Janet selling $43 on Jul 31, 2024.
Where does INM insider trading data come from?
From the Form 4 filings InMed Pharmaceuticals Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.